Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) EBIT (2020 - 2025)

Historic EBIT for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to -$7.3 million.

  • Rani Therapeutics Holdings' EBIT rose 3849.48% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$44.7 million, marking a year-over-year increase of 1362.79%. This contributed to the annual value of -$53.3 million for FY2024, which is 1934.22% up from last year.
  • Per Rani Therapeutics Holdings' latest filing, its EBIT stood at -$7.3 million for Q3 2025, which was up 3849.48% from -$10.5 million recorded in Q2 2025.
  • In the past 5 years, Rani Therapeutics Holdings' EBIT registered a high of -$5.2 million during Q1 2021, and its lowest value of -$27.8 million during Q3 2021.
  • Its 5-year average for EBIT is -$13.9 million, with a median of -$13.8 million in 2022.
  • Per our database at Business Quant, Rani Therapeutics Holdings' EBIT tumbled by 88270.25% in 2021 and then skyrocketed by 4117.56% in 2022.
  • Over the past 5 years, Rani Therapeutics Holdings' EBIT (Quarter) stood at -$13.4 million in 2021, then crashed by 30.83% to -$17.5 million in 2022, then increased by 23.16% to -$13.4 million in 2023, then dropped by 11.34% to -$15.0 million in 2024, then skyrocketed by 51.48% to -$7.3 million in 2025.
  • Its last three reported values are -$7.3 million in Q3 2025, -$10.5 million for Q2 2025, and -$12.0 million during Q1 2025.